首页> 外文学位 >HIV-1 Cell-to-Cell Transmission: Mechanisms and Therapeutic Implications.
【24h】

HIV-1 Cell-to-Cell Transmission: Mechanisms and Therapeutic Implications.

机译:HIV-1细胞间传播:机制和治疗意义。

获取原文
获取原文并翻译 | 示例

摘要

Human immunodeficiency virus type 1 (HIV-1), a member of the Lentivirus genus of the Retroviridae family, is the causative agent of Acquired Immunodeficiency Syndrome (AIDS). Like many other animal viruses, HIV-1 is able to spread by either a cell-free mode through the extracellular space or by cell-to-cell transmission involving direct cell-cell contacts. The factors that determine whether a virus spreads by either pathway are poorly understood. Here, we developed quantitative assays to analyze the relative contribution of HIV-1 cell-free and cell-to-cell transmission in any given co-culture assays. We demonstrated that HIV-1 can spread by a cell-free pathway if all steps of the viral replication cycle are efficiently supported in highly permissive cells. However, when we systematically introduced barriers to the cell-free path at various steps, HIV-1 transmission became contact-dependent. Importantly, we demonstrated that pre-existing barriers in both donor and target cells contribute to contact-dependent transmission. Thus, our model offered an explanation for conflicting reports on the contribution of HIV-1 cell-to-cell transmission, which is the result of specific features in donor and target cell types.;HIV-1 cell-to-cell transmission allows for 2-3 orders of magnitude more efficient virus spreading than the cell-free transmission and can overcome multiple barriers imposed on cell-free virus. We demonstrate that this also includes barriers at the step of assembly and release of cell-free HIV-1. The host factor Tsg101, while essential for cell-free release, is not required for efficient HIV-1 cell-to-cell transmission in various T cells. Our results suggest that the underlying mechanism of Tsg101 independence in HIV-1 cell-to-cell transmission is compensation by another cellular factor ALIX. Our data support a model whereby the localization and concentration of viral and cellular factors at sites of cell-cell contact allows for efficient HIV-1 cell-to-cell transmission.;We then applied our quantitative assays to carefully characterize the efficacy of ART drugs to interfere with HIV-1 cell-to-cell transmission. Our data confirmed the previously reported failure of tenofovir and ziduvudine to efficiently interfere with HIV-1 cell-to-cell transmission and extended this observation to raltegravir. Thus, HIV-1 cell-to-cell transmission is more resistant to various antiretroviral inhibitors, just like it can overcome various barriers in donor and target cells that are effectively against cell-free virus. Interestingly, we also found that efavirenz and saquinavir remain effective against HIV-1 cell-to-cell transmission. Our data suggest that competitive inhibitors are less efficient in interfering with HIV-1 cell-to-cell transmission and the success of allosteric reverse transcriptase and protease inhibitors in ART is in part due to their efficacy against HIV-1 cell-to-cell transmission.;Host factors are potential targets to develop antiretroviral therapies. However, the example of Tsg101 suggest that some host factors that are required for the spread of cell-free HIV-1 are less important during cell-to-cell transmission. Therefore, it is critical to identify novel host factors required for HIV-1 replication that cannot be overcome during cell-to-cell transmission. Towards this end, we further developed a quantitative assay for HIV-1 cell-to-cell transmission suitable for high-throughput screening and performed a kinase/phosphatase genome-wide siRNA screen. We identified WW domain binding protein 11 (WBP11) as a novel factor required for HIV-1 assembly and budding that cannot be overcome in cell-to-cell transmission. Future work should concentrate on identifying a potential role for WBP11 in regulating the viral genome during nuclear export, translation, cytoplasmic trafficking and virus assembly.;In summary, the work accomplished in this thesis project - the establishment o f quantitative assays and a mechanistic understanding o f HIV-1 cell-to-cell transmission provide a powerful framework to outline strategies for the successful therapeutic control o f HIV-1, through the use of current ART regimens and targeting host factors that cannot be overcome during HIV-1 cell-to-cell transmission.
机译:人类免疫缺陷病毒1型(HIV-1)是逆转录病毒科慢病毒属的成员,是获得性免疫缺陷综合症(AIDS)的病原体。像许多其他动物病毒一样,HIV-1可以通过无细胞模式传播到细胞外空间,也可以通过涉及直接细胞间接触的细胞间传播来传播。决定病毒是否通过任一途径传播的因素了解甚少。在这里,我们开发了定量分析,以分析在任何给定的共培养分析中,HIV-1无细胞和细胞间传播的相对贡献。我们证明,如果高度允许的细胞有效支持病毒复制周期的所有步骤,HIV-1可以通过无细胞途径传播。但是,当我们在各个步骤中系统性地向无细胞途径引入障碍时,HIV-1的传播就变得依赖于接触。重要的是,我们证明了供体细胞和靶细胞中既存的壁垒均会导致接触依赖性传播。因此,我们的模型为关于HIV-1细胞间传播贡献的相互矛盾的报告提供了解释,这是供体和靶细胞类型特定特征的结果.HIV-1细胞间传播可以实现与无细胞传播相比,病毒传播的效率提高了2-3个数量级,并且可以克服对无细胞病毒施加的多个障碍。我们证明,这还包括在组装和释放无细胞HIV-1的步骤中的障碍。宿主因子Tsg101虽然对于无细胞释放至关重要,但对于各种T细胞中有效的HIV-1细胞间传播来说并不需要。我们的结果表明,HIV-1细胞之间的Tsg101独立性的潜在机制是由另一种细胞因子ALIX进行的补偿。我们的数据支持一个模型,通过该模型,病毒和细胞因子在细胞与细胞接触部位的定位和浓度可以实现有效的HIV-1细胞间传播。;然后,我们应用了定量分析方法来仔细表征ART药物的功效干扰HIV-1细胞间的传播。我们的数据证实了先前报道的替诺福韦和齐多夫定不能有效干扰HIV-1细胞间的传播,并将这一发现扩展到了raltegravir。因此,HIV-1的细胞间传播对各种抗逆转录病毒抑制剂更具抵抗力,就像它可以克服供体和靶细胞中有效抵抗无细胞病毒的各种障碍一样。有趣的是,我们还发现依非韦伦和沙奎那韦仍然可以有效抵抗HIV-1细胞间的传播。我们的数据表明竞争性抑制剂在干扰HIV-1细胞间传播方面效率较低,而变构逆转录酶和蛋白酶抑制剂在ART中的成功部分归因于它们对抗HIV-1细胞间传播的功效宿主因素是发展抗逆转录病毒疗法的潜在目标。但是,Tsg101的例子表明,无细胞HIV-1传播所需的一些宿主因子在细胞间传播中的重要性较低。因此,至关重要的是要确定HIV-1复制所需的新型宿主因子,这些新宿主因子在细胞间传播过程中无法克服。为此,我们进一步开发了适用于高通量筛选的HIV-1细胞间传播定量检测方法,并进行了激酶/磷酸酶全基因组siRNA筛选。我们确定了WW域结合蛋白11(WBP11)是HIV-1组装和发芽所必需的新因子,在细胞间传播中无法克服。未来的工作应集中在确定WBP11在核输出,翻译,细胞质运输和病毒组装过程中在调节病毒基因组中的潜在作用。总之,本项目完成的工作-建立定量测定和对机理的机械理解HIV-1细胞间的传播提供了一个强大的框架,可通过使用当前的抗逆转录病毒疗法以及靶向在HIV-1细胞间无法克服的宿主因素来概述成功治疗HIV-1的策略传播。

著录项

  • 作者

    Zhong, Peng.;

  • 作者单位

    Yale University.;

  • 授予单位 Yale University.;
  • 学科 Biology Cell.;Biology Microbiology.;Biology Virology.
  • 学位 Ph.D.
  • 年度 2013
  • 页码 186 p.
  • 总页数 186
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号